Zeiss selects Eyemaginations

Article

Eyemaginations has been selected by Carl Zeiss Meditec to release two new patient education animations.

Zeiss selects Eyemaginations

Eyemaginations has been selected by Carl Zeiss Meditec to release two new patient education animations.

Zeiss has contracted Eyemaginations to create animations that could explain the GDx Scanning Laser Polarimeter technology and the Stratus Optical Coherence Tomography (OCT). In order to achieve this, the company produced two segments that combine detailed visuals of the optic nerve and the retinal nerve fibre layer accompanied by an educational video.

The new animations will be included in the 4.3 version of 3D-Eye Office from Eyemaginations.

IntraLase & Escalon on better terms

IntraLase has entered into an agreement with Escalon Medical to settle all outstanding disputes and litigation between the parties.

Under the terms of the agreement, IntraLase will make a payment of $9.6 million to Escalon, in exchange for all pending litigations to be dropped. Full ownership of all patents and intellectual property formerly licensed from Escalon will be obtained by IntraLase and all IntraLase obligations under the parties' license agreement will terminate. The payment will also cover all outstanding royalties owed or alleged to be owed by IntraLase to Escalon.

Synergetics found guilty in patent battle

A US District Judge has now ruled on all outstanding summary motions in Iridex's patent infringement suit against Synergetics, relating to Patent No. 5,085,492.

The jury will now only have to decide the amount of damages caused by Synergetics' infringement, whether the infringement was wilful and whether Iridex's patent is invalid for obviousness. The court will also decide whether Iridex's right to recover damages is limited by the equitable doctrines of laches and estoppel.

The court ruled that Iridex is entitled to summary judgement on each of Synergetics' non-patent counterclaims of false advertising, defamation and injurious falsehood.

The trial is due to begin on 16 April 2007.

ORBIS Day announced at 25th anniversary

The 1st of March was declared "ORBIS Day" in New York City, USA, by Mayor Michael R. Bloomberg at the celebration of ORBIS's 25th anniversary at the United Nations.

ORBIS International, best known for the world's only Flying Eye Hospital, is dedicated to saving sight across the world and more than 80 heads of state and the past three secretaries general of the UN gathered to recognize its achievements.

To recognize the 28 million people, worldwide, who are needlessly blind, the tower lights of the Empire State building were turned off for 28 minutes and, when re-lit, the building was lit in blue and white in honour of ORBIS.

A call for global action was launched with a $10 million gift from A.L. Ueltschi, chairman of FlightSafety International and chairman of the ORBIS International board of directors; the largest gift ever received by the organisation.

Numerous companies have also pledged money, and it is hoped that the overall fund will total around $100 million.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.